Baker Botts' Life Sciences Practice embraces the innovation that drives today's life sciences industry. We recognize this innovation involves not only ground-breaking science, but also an understanding of the business challenges inherent and unique to the industry. Our Life Science lawyers have the scientific acumen to understand and protect our clients' innovations, as well as the experience to address the myriad of legal issues involved in bringing a pharmaceutical product, medical device, or research/industrial tool to market. Our team of attorneys understand the unique intellectual property, transactional, corporate, and litigation issues that surround products and services in the life science industry, which allows us to effectively and efficiently help our clients maneuver through these challenges.
Our team of Life Sciences lawyers, including over 50 intellectual property lawyers and scientific advisors, understands that this industry is evolving at an incredible pace. Through our daily interactions and strategic client relationships, we recognize the life sciences industry is no longer defined solely by pharmaceutical, biological, and medical sciences. Instead,the industry has developed to cross into an array of scientific and technological disciplines.
An important differentiator of our Life Sciences Practice is the active integration of our high-technology colleagues, born of our firm's cultural emphasis on cross-discipline collaboration. Our Life Sciences lawyers are adept at linking to the full range of intellectual assets of the over 180 IP lawyers, patent agents, and scientific advisors firmwide, collectively holding more than 220 scientific and advanced technical degrees spanning diverse fields such as biology, chemistry, chemical engineering, food science, material science, mathematics, mechanical engineering, physics, computer science, electrical engineering and more.
This integration has particularly benefited our clients involved with the convergence of life sciences and high-technology, including the associated issues with hardware, software, data acquisition, data analysis and data management, among others. This breadth and diversity of technical backgrounds affords our Life Sciences Practice the aptitude to manage the most complex and diverse technological projects, including the protection, enforcement and commercialization of intellectual property, as the life sciences industry continues its evolution.
Furthermore, our Life Sciences Practice extends to and integrates a wealth of transactional and litigation experience and attorneys intimately involved with the life sciences industry, including corporate, antitrust and white collar crime issues and matters. We regularly advise clients globally and with interdisciplinary teams to provide a collaborative mix of commercial transaction and regulatory compliance experience, such as with antitrust and white-collar and corporate investigations. Understanding the intersection of the life sciences industry and the commercial business objectives enhances our ability to add value to a host of complex client issues.
Legal and Technical Experience
Our Life Sciences lawyers provide a valuable combination of advanced academic backgrounds and sophisticated experience in organic and medicinal chemistry, pharmacology, biochemistry, molecular and cell biology, genetics, immunology, virology and microbiology, chemical engineering, biomedical engineering, physics, mechanical engineering and electronics. Our IP technical bench includes over 15 lawyers and professionals with PhDs/MDs in various biological and chemical disciplines.
Similarly, our life sciences clients are involved in all areas of medicine and health care, including oncology, neurology and psychiatry, allergy and immunology, diagnostics, structural heart and cardiovascular disease, genetic disease, metabolic disease, orthopedics and dentistry, infectious disease and pain management, as well as food sciences and veterinary medicine.
Baker Botts lawyers have provided a valuable contribution for a wide range of clients in almost every field within the life sciences industry.
Our clients include:
- large branded pharmaceutical companies
- established and emerging biotechnology companies
- international medical devices companies
- food and beverage companies
- universities and research institutions
- start-up and early stage life sciences companies
- companies in the energy and agricultural sectors with diverse life sciences-related technologies, including biofuels, industrial enzymes and genetically-modified plants and seeds
Services and Cross Collaboration
Our Life Sciences IP lawyers understand the complexities of the array of technologies presented by our clients, and effectively assist our clients in pursuing IP protection for these technologies, including patent protection and trade secret guidance. We also help our clients implement business and commercial objectives by strategically developing IP portfolios, as well as providing a full gamut of IP management needed in this competitive industry. Such assistance includes undertaking sophisticated due diligence reviews of industries, companies and related IP portfolios, evaluating freedom to operate for new technologies and product developments, and rendering opinions and/or counsel for clients with intellectual property strategy.
Baker Botts also assists our life sciences clients with the full range of business development, corporate venture and transactional needs within the life sciences industry, including identifying and evaluating targets for potential investment, mergers, and acquisitions, as well as structuring and negotiating inbound and outbound licensing agreements, collaboration agreements, joint ventures, pre-clinical and clinical trial agreements, and manufacturing agreements.
When necessary, our Life Sciences IP lawyers enforce our clients IP against third parties, or defend our clients from claims of infringement, whether as plaintiffs or defendants, in trial and appellate courts. We are regularly involved in global IP disputes, including opposition proceedings before the European, Japanese, Australian and Indian Patent Offices.
Our corporate, antitrust, and white-collar and corporate investigations practice groups share the same life sciences focus as our intellectual property group, and have handled a wide spectrum of legal issues with clients in the life sciences industry. These practice groups work closely together to deliver "high-quality legal advice... in a way that meets both cost and timeliness expectations."
As a team, our Life Sciences lawyers firmwide provide seasoned legal counseling and cross-legal collaboration, through which we can help you better understand and anticipate the issues, objectives and needs you may face.
Contacts
Related Experience
-
results
Page of
Columbia University - Artificial Intelligence Patent Applications
University of Pennsylvania - Patent Applications
Johnson Matthey Plc. - Sale of its Health Business to Altaris Capital Partners
FUJIFILM Cellular Dynamics, Inc. - Strategic Research and Development Alliance and Licensing Transaction
Oxford Nanopore Technologies Limited - Patent and Non-Patent Related Matters
Baylor College of Medicine - Gensetix, Inc. et al v. Baylor College Of Medicine et al - Patent Infringement
Oxford Nanopore - Pacific BioSciences v. Oxford Nanopore - Patent Infringement
Oxford Nanopore - Illumnia v. Oxford Nanopore Technologies - Patent Litigation
Chemspeed Technologies - Freeslate v. Chemspeed Technologies- Patent Litigation
Pozen - Pozen Inc. v. Dr. Reddy's Laboratories et al. - Patent Infringement
Pharmacosmos - Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc. - Patent Litigation - Inter Partes Review
ZS Pharma, Inc. - Initial Public Offering
Columbia University - Intellectual Property Services
Lexion Medical LLC - SurgiQuest Inc. v. Lexion Medical LLC - False Advertising
University of Pennsylvania - Patent Portfolio Management
European Pharma Company - IP Counseling, Licensing, and Litigation
Medical Device Company - Patent Challenges
University of Pennsylvania - Patent Prosecution
News
FTC Moves to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics
Wall Street JournalWall Street Journal
Baker Botts Represents Stoller Group’s Trustees in Sale to Corteva Agriscience
Baker Botts Represents Celanese in $11 Billion Acquisition of DuPont's Mobility and Materials Business
Legal 500 US and Chambers USA 2022 Rankings Highlight Baker Botts’ Technology Expertise
Baker Botts Elects 18-Member Partnership Class
Baker Botts Advises Viracorp On Partnership with Lancaster University to Produce New Nasal COVID-19 Vaccine
Baker Botts Achieves Favorable ITC Final Determination for CMC Materials
Baker Botts Welcomes Financial Restructuring Partner in New York
Baker Botts Advises Resilia Pharmaceuticals, Inc. in License Agreement for Solace Eczema Cream
Baker Botts Improves Rankings and Individual Recognitions in The Legal 500 UK 2022 Edition
Highly Regarded Technology Partner Joins Baker Botts’ Corporate Practice in Dallas
Partner Cynthia Cole Elected to Leaderxxchange Advisory Board
Baker Botts’ Transactional Practices Shine in Legal 500 and Chambers USA Rankings
Baker Botts Continues Ascent Up Legal 500 US Rankings
PacBio v. Oxford Nanopore
Global Legal ChronicleGlobal Legal Chronicle
Court of Appeals for the Federal Circuit Affirms Jury Decision to Invalidate Certain PacBio Patents
Fed. Circ. Backs Oxford Nanopore's DNA Tech IP Trial Victory
Law360Law360
Federal Circuit Denies Retrial to Pacific Biosciences in DNA-Sequencing Patent Dispute
Law StreetLaw Street
Federal Circuit Upholds Delaware Jury's Finding in DNA Sequencing Patent Case
Delaware Business Court InsiderDelaware Business Court Insider
Fed. Circ. Affirms PacBio Loss on its DNA-Sequencing Patent Claims
ReutersReuters
Oxford Nanopore’s Trial Win Over DNA Sequencing Patents Upheld
Bloomberg LawBloomberg Law
Baylor, Gensetix Agree To Drop Cancer Patent Fight For Good
Law360Law360
Law360's 2021 Life Sciences Editorial Board
Law360Law360
Baker Botts Welcomes Prominent Cross-Border M&A Partner in New York
Baker Botts Promotes 19 Lawyers to Special Counsel
Baker Botts Elects 12-Member Partnership Class
Baker Botts’ IP Department Secures Highest Win Rate Nationally in Patent Challenges Over Last Five Years
Supreme Court Asked to Step in Amid Genus Claims Losing Streak
Bloomberg LawBloomberg Law
Baker Botts Continues to Expand West Coast IP Practice with Addition of Prominent Partner
How Will FDA Regulate Disease-Sniffing Dogs?
Update MagazineUpdate Magazine
Full Economic Impact of COVID-19 on Life Sciences Industry Still Uncertain
MedTech IntelligenceMedTech Intelligence
Virus Researchers Race to File Patents Ahead of Research Reveal
Bloomberg LawBloomberg Law
Virus Collaborations Could Create Messy Patent Questions
Bloomberg LawBloomberg Law
Law360's 2020 Life Sciences Editorial Advisory Board
Law360Law360
Pacific Biosciences of California Inc. v. Oxford Nanopore Technologies Inc
Global Legal ChronicleGlobal Legal Chronicle
And the LOTW Runners Up...
Litigation DailyLitigation Daily
Law360's Weekly Verdict: Legal Lions & Lambs
Law360Law360
Del. Jurors Clear Oxford Nanopore In DNA Tech Patent Suit
Law360Law360
Patent Trial Opens Over DNA Tool Used To ID Coronavirus
Law360Law360
Congress in Hot Seat to Fix Patent Law After High Court Denials
Bloomberg LawBloomberg Law
Justices Slam Door On Pleas To Redo Patent Eligibility
Law360Law360
New York-Based Partner Robert Scheinfeld Named Co-Chair of Baker Botts’ Globally Recognized Intellectual Property Department
Law360's Life Sciences Editorial Advisory Board
Law360Law360
Lawmakers Eye Biosimilar-Delay Deals, But None Are Here Yet
Law360Law360
Fed. Circ. Says UK DNA Sequencers Don’t Infringe IP In US
Law360Law360
Thought Leadership
Antitrust M&A Strategic Path Re-Opened by the Amgen/Horizon Conduct Settlement
Client UpdatesAntitrust Update
U.S. Supreme Court Affirmed Patent Enablement Requirement in Amgen
Client UpdatesIntellectual Property Update
Intellectual Property Report
Client UpdatesSpring Budget 2023: Chancellor Introduces Incentives for Tech Investments in the UK
Client UpdatesIntellectual Property Report
Client UpdatesFreedom to Operate Analysis Three Strategies to Efficiently Achieve Robust Results
Client UpdatesIntellectual Property Update
March-in Rights: Implications from the COVID-19 Pandemic
External ArticlePratt's Government Contracting Law Report
U.S. Supreme Court Grants Certiorari to Address Patent Enablement Requirement
Client UpdatesIntellectual Property Update
Intellectual Property Report
Client UpdatesNew Executive Order Details CFIUS National Security Factors
Client UpdatesInternational Trade Update
Intellectual Property Report
Client UpdatesIntellectual Property Report
Client UpdatesPre-Litigation Investigations and Due Diligence
External ArticlePre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, 3rd Edition, Chapter 14, American Bar Association Book Publishing
Addressing Open Source Software Issues as Life Science Companies Embrace Hi-Tech Solutions
External ArticleIntellectual Property Report
Client Updates
Addressing Open Source Software Issues as Life Science Companies Embrace Hi-Tech Solutions
Client UpdatesIntellectual Property Report
Intellectual Property Report
Client UpdatesRetroactive Authorization of Sales and the Doctrine of Patent Exhaustion
Client UpdatesIntellectual Property Report
Federal Circuit Confirms ANDA Notice Letters Are Not Acts of Infringement for Venue Purposes
External ArticleNew York Law Journal, Volume 266, No. 99
Intellectual Property Report
Client UpdatesPandemic Patent Jury Trials Report: August 2020 - September 2021
Client UpdatesOn the Interface of Intellectual Property and Antitrust: The Case of Divisional Patent Applications in the Pharmaceutical Sector
Client UpdatesAntitrust Update
Intellectual Property Report
Client UpdatesU.S. Tax Court Clarifies the Tax Implications of Generic Drug Litigation
Client UpdatesTax Update
Intellectual Property Report
Client Updates
Masks Off: Navigating the COVID-19 Vaccine Era
Client UpdatesPrivacy and Data Security Update
Biden Administration First 100 Days Weekly Report - Episode 11
Client UpdatesWinter Storm Uri Consumer Resource Guide
Client UpdatesIntellectual Property Report
Client UpdatesAnimal-Based Medical Diagnostics: A Regulatory Problem
External ArticleFood and Drug Law Journal, Volume 75, Number 3
Considerations for a Biden Administration – Intellectual Property
VideoHow Will FDA Regulate Disease-Sniffing Dogs?
External ArticleFDLI Update Magazine
Advanced Biotechnology Claim Drafting Issues
Speeches & PresentationsSpeaker, Practicing Law Institute's Advanced Prosecution Workshop
Events
Recent
JP Morgan Healthcare Conference Private Reception
The U.S. Supreme Court's Impact on IP
Life Sciences 2021: The Road Ahead
A Conversation with Walter Isaacson: The Biotech Revolution and the Woman Who Launched It
In celebrating International Women's Day, Baker Botts is a proud sponsor, in partnership with the Chapter Network of The National Association of Corporate Directors, of the virtual conversation with Walter Isaacson and Dr. Helene Gayle, President & CEO of the Chicago Community Trust, on Monday, March 8, 2021 2:00 p.m. - 3:00 p.m. CT.
2020 JP Morgan Healthcare Conference Reception
Baker Botts and Salem Partners will be hosting a private reception during the J.P.Morgan Healthcare Conference to be held at Jasper's Corner Tap and Kitchen on Monday January 13, 2020.